RHO6 Stock Overview
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Roche Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 35.00 |
52 Week High | CHF 38.50 |
52 Week Low | CHF 27.10 |
Beta | 0.15 |
11 Month Change | 0.79% |
3 Month Change | -2.98% |
1 Year Change | 14.19% |
33 Year Change | -21.15% |
5 Year Change | 3.40% |
Change since IPO | 236.54% |
Recent News & Updates
Recent updates
Shareholder Returns
RHO6 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -1.4% | -1.9% | -1.4% |
1Y | 14.2% | -15.7% | 11.8% |
Return vs Industry: RHO6 exceeded the German Pharmaceuticals industry which returned -15.7% over the past year.
Return vs Market: RHO6 exceeded the German Market which returned 11.8% over the past year.
Price Volatility
RHO6 volatility | |
---|---|
RHO6 Average Weekly Movement | 3.9% |
Pharmaceuticals Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.6% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RHO6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RHO6's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1896 | 103,605 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas.
Roche Holding AG Fundamentals Summary
RHO6 fundamental statistics | |
---|---|
Market cap | €227.39b |
Earnings (TTM) | €11.28b |
Revenue (TTM) | €64.36b |
19.9x
P/E Ratio3.5x
P/S RatioIs RHO6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RHO6 income statement (TTM) | |
---|---|
Revenue | CHF 60.58b |
Cost of Revenue | CHF 15.43b |
Gross Profit | CHF 45.16b |
Other Expenses | CHF 34.54b |
Earnings | CHF 10.62b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 13.33 |
Gross Margin | 74.54% |
Net Profit Margin | 17.53% |
Debt/Equity Ratio | 104.8% |
How did RHO6 perform over the long term?
See historical performance and comparison